A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
about
Characterization of the commercially-available fluorescent chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a marker for chloroquine resistance and uptake in a 96-well plate assaySimplified Reversed Chloroquines To Overcome Malaria Resistance to Quinoline-Based DrugsChlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT.Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparumExpanding the Antimalarial Drug Arsenal-Now, But How?Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum.Synthesis, structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds.Malaria biology and disease pathogenesis: insights for new treatments.Stereospecific synthesis of 23-hydroxyundecylprodiginines and analogues and conversion to antimalarial premarineosins via a Rieske oxygenase catalyzed bicyclizationContrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates.Antimalarial activity of natural and synthetic prodiginines.Reversed chloroquine molecules as a strategy to overcome resistance in malaria.Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities.Overcoming Chloroquine Resistance in Malaria: Design, Synthesis, and Structure-Activity Relationships of Novel Hybrid Compounds.Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design.Structural modifications of quinoline-based antimalarial agents: Recent developments.Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.Dual-functioning antimalarials that inhibit the chloroquine-resistance transporter.Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream?Antimalarial chemotherapy: orally curative artemisinin-derived trioxane dimer esters.Synthesis and Antiplasmodial Activity of Novel Chloroquine Analogues with Bulky Basic Side Chains.Malaria-infected mice live until at least day 30 after a new artemisinin-derived thioacetal thiocarbonate combined with mefloquine are administered together in a single, low, oral dose.4-aminoquinoline-triazine-based hybrids with improved in vitro antimalarial activity against CQ-sensitive and CQ-resistant strains of Plasmodium falciparum.Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas.Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-chloro-4-aminoquinolines.The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents.Progress in the development of Reversed Chloroquine molecules as antimalarial therapy.Synthesis of novel hybrid molecules from precursors with known antiparasitic activity.Quinoline-Based Hybrid Compounds with Antimalarial Activity.Targeting Channels and Transporters in Protozoan Parasite Infections.Current and Future Strategies for Improving Drug Discovery Efficiency
P2860
Q28544110-6FF09879-8A08-496E-B767-2CAFB911D154Q33601788-94CEEAB0-BDA7-4474-B1FE-A27F20D3C107Q33636449-87477D8D-3B52-4D36-9329-3F50B6165750Q33797050-43C66211-3FB8-4E5D-AB9F-B4A823A2203FQ33916111-277C0B78-5EDA-411B-A7CD-D3FF7EEC98C4Q34077604-62C60A41-4E2D-426C-94C1-D57798E93ECAQ34090478-8439E874-A429-4184-9E67-B107BCF73536Q34129945-764159F7-39DD-4CFB-8C24-F5567596622BQ34579700-207835C6-8DCE-4960-8E10-643C5E874EA9Q34661869-53F01093-3D9A-4D5D-9675-68A3B87D742CQ35684833-2EEA3A5C-3B8E-41FA-A910-A794D5F45A64Q35828085-E44D6C87-FB5B-430F-BBCF-077FBD1B40E8Q35969822-4A404A7F-D69E-4766-A701-79489E3A2E71Q36106723-4652439D-983F-4B68-AD21-A6633F859A20Q36888033-66434AC5-8B14-49BE-800F-CE56683E480DQ37852563-E7F4BF39-9DA8-4742-8ACA-72ACD972F96AQ37911288-C1B13746-2332-4979-AAE3-803A04E8ACADQ37979631-4A68288C-2C0C-4DD7-B583-B99229D9FD09Q38093645-04421C43-216D-4C1B-A612-97833D8E1061Q39176524-30B0F627-51F3-4E2A-990E-7F3DD80FD3D7Q41614007-2CF860AA-02E5-457C-9569-11A3CE65C07BQ41917145-8BC7029C-A128-4935-BE84-732DB6C1EE50Q41920854-45A44BEB-3DE9-4256-9F21-494C684CD70BQ41927067-BF2D7E3A-08F5-434C-84BA-AF1ADB786ED7Q41939714-82E00B7A-1AD2-4EEC-BF20-4A67C12E600CQ41941261-722B712F-DE48-4178-A03C-4B7B4988C666Q42000397-369F2890-F94E-4908-B053-275082E207DCQ42744283-3B6A82A9-E9A7-4505-B02E-694BB1CC97DDQ45973120-D79FBE24-8A11-41B3-8256-CDF30FB7D9EEQ46041643-DE876B4B-C1AE-4BEA-BF7A-340FC1BCAA84Q48019642-15EE2CE0-34ED-43C4-88FC-27B32C9A985EQ52594992-2D6D96C1-E36F-4948-85EF-C1FA3B12EEFFQ58636775-E0F6210F-2BEF-4A8A-BEA8-50326455AC81
P2860
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@ast
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@en
type
label
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@ast
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@en
prefLabel
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@ast
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@en
P2093
P2860
P356
P1476
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
@en
P2093
Audrey Selzer
David H Peyton
Jane Xu Kelly
Martin J Smilkstein
Michael K Riscoe
Steven J Burgess
P2860
P304
P356
10.1021/JM060399N
P407
P577
2006-09-01T00:00:00Z